glp 1 and sglt2 Perspectives in weight control in diabetes – inhibitors GLP-1–glucagon dual agonism SGLT2 inhibitors or GLP-1 receptor
Description
Mutation of carboxyl-terminal threonine residues in human m3 muscarinic acetylcholine receptor modulates the extent of sequestration and desensitization
The trade-off
We do it all the time in women's medicine all the time
Patients with diabetes taking semaglutide should be particularly vigilant, as they may experience atypical or less pronounced symptoms due to diabetic neuropathy affecting sensory perception
Strategies include: Adjusting insulin frequency or type
doi: 10.1136/bmj.j4849 10 CooperTCSimmonsEBWebbKBurnsJLKushnerRF
